search
Back to results

Efficacy and Safety Study of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Bone Marrow (MatriBone)

Primary Purpose

Degenerative Osteoarthritis, Degenerative Lumbar Vertebra

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
The Transforaminal Lumbar Interbody Fusion (TLIF) surgery
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Degenerative Osteoarthritis focused on measuring Orthopedic Procedures, Spine, Interbody fusion, Arthrodesis, Lumbar Vertebrae, CT Scan, Spine balance, Instrumented fusion, Posterior fusion, Degenerative spine, painful

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged between 18 and 65 years old.
  • Body mass index lower than 35
  • Degenerative osteoarthritis painful and invalidating degenerative lumbar vertebra for at least 6 months and resistance fighter in the conservative treatment
  • Narrow lumbar canal and\or spondylolisthesis with neurological disorder associated with signs of primary instability or induced to neurological liberation
  • Patient requiring a surgery on a single interbody level.
  • Given informed consent
  • Patient with French health system

Exclusion Criteria:

  • For women: no efficient contraception (intra uterine device, or contraceptive pill)
  • Pregnant or feeding women
  • Surgery zone local infection local
  • Lumbar interbody fusion of more than two levels
  • Spondylolisthesis of high rank (stage 3 or 4 of the classification of Meyerding)
  • Scoliosis lumbar vertebra gives a complex to (Cobb angle> 40°)
  • All surgical contraindications
  • Severe hyperparathyroidism: calcium > 2,45 mmol/l and [PTH] ≥ 50pg / ml
  • Uncontrolled diabetes (untreated or non stabilized by treatment)
  • Long corticoid treatment (more than 6 months and stopped since less than 3 months)
  • Current Chemotherapy or during the last three months
  • Antecedent of regional radiotherapy
  • All contraindication to MatriTM BONE: osteomyelitis, bone degenerative disease or necrosis of surgery site.
  • Known turned out Osteoporosis untreated (dexa: > 2 DS)
  • Subject participating in another research including a period of always current exclusion in the pre-inclusion
  • Person placed under protection of justice
  • Severely altered physical and\or psychological Health, which according to, the investigator, can affect to participant's compliance to the study.

Sites / Locations

  • Unité d'Orthopédie-Traumatologie rachis II, Pellegrin

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TLIF surgery

Arm Description

Outcomes

Primary Outcome Measures

patients' proportion which an intervertebral fusion
The main assessment criteria of this study are patients' proportion which an intervertebral fusion is documented to CT scanners The intervertebral fusion is documented by the revealing of at least an osseous continuous span of a vertebral level in the other one on one of three CT scan slides centred on the cage.

Secondary Outcome Measures

NOTION OF TOLERANCE: Frequency and gravity of unwanted Adverse Events linked to the procedure and\or the use of the biomaterial
Frequency and gravity of unwanted Adverse Events linked to the procedure and\or the use of the biomaterial: O Inflammatory or allergic reaction to the tested product (VS and CRP before inclusion). Non-union turned out and painful Invalidating lumbar pain Infection on the operated site
Evaluation of the pain
Evaluation of the pain with an analogical visual scale (EVA)
Quality of life evaluation
Quality of life evaluation by means of OSWESTRY and SF-36 scales

Full Information

First Posted
April 6, 2011
Last Updated
June 29, 2021
Sponsor
University Hospital, Bordeaux
Collaborators
Biom'Up France SAS
search

1. Study Identification

Unique Protocol Identification Number
NCT01335243
Brief Title
Efficacy and Safety Study of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Bone Marrow
Acronym
MatriBone
Official Title
Multicentric, Prospective Study of Efficacy and Safety of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Marrow
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
June 30, 2015 (Actual)
Study Completion Date
June 30, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Biom'Up France SAS

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main objective of this clinical study is the estimation of the rate of intersomatic fusion observed 12 months after lumbar interbody fusion by posterior approach with PEEK interbody cage of fusion in PEEK performed with autologous bone of decortication and osseous substitute with a biomaterial (MatriBONE associated with the autologous bone marrow), associated with a posterolateral bone graft performed with MatriBone waxed with bone marrow. Indication is dedicated for patients by painful degenerative osteoarthritis, by narrow lumbar canal and\or spondylolisthesis.
Detailed Description
This clinical study corresponds to a TLIF surgery using a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion. Biomaterial MATRITM BONE: Device of class III, with marking IT in the indication of arthrodesis. It will be administered during the lumbar interbody fusion's procedure. The material is a matrix of collagen mineralized containing a homogeneous mixture of collagen cleansed of type I+III and an osseous biphasic substitute HA / TCP. The proportion of both constituents is 90 % of osseous substitute for 10 % of collagen en masse. The collagen is reduced in approximately 1 month and the osseous substitute leads to an osseous reshaping in 6 - 9 months approximately. The follow up will last 12 months with 2 visits (6 and 12 months after surgery), 2 CT scan slides before inclusion and at 12 months, classical X-rays before inclusion and at 6 and 12 months, questionnaires (visual analogic scale for pain, and quality of life with OSWESTRY and SF36 scales) before inclusion and at 6 and 12 months, and biological exams (CRP/VS, for inflammation) at each visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Osteoarthritis, Degenerative Lumbar Vertebra
Keywords
Orthopedic Procedures, Spine, Interbody fusion, Arthrodesis, Lumbar Vertebrae, CT Scan, Spine balance, Instrumented fusion, Posterior fusion, Degenerative spine, painful

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TLIF surgery
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
The Transforaminal Lumbar Interbody Fusion (TLIF) surgery
Intervention Description
The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
Primary Outcome Measure Information:
Title
patients' proportion which an intervertebral fusion
Description
The main assessment criteria of this study are patients' proportion which an intervertebral fusion is documented to CT scanners The intervertebral fusion is documented by the revealing of at least an osseous continuous span of a vertebral level in the other one on one of three CT scan slides centred on the cage.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
NOTION OF TOLERANCE: Frequency and gravity of unwanted Adverse Events linked to the procedure and\or the use of the biomaterial
Description
Frequency and gravity of unwanted Adverse Events linked to the procedure and\or the use of the biomaterial: O Inflammatory or allergic reaction to the tested product (VS and CRP before inclusion). Non-union turned out and painful Invalidating lumbar pain Infection on the operated site
Time Frame
12 months
Title
Evaluation of the pain
Description
Evaluation of the pain with an analogical visual scale (EVA)
Time Frame
12 months
Title
Quality of life evaluation
Description
Quality of life evaluation by means of OSWESTRY and SF-36 scales
Time Frame
12 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged between 18 and 65 years old. Body mass index lower than 35 Degenerative osteoarthritis painful and invalidating degenerative lumbar vertebra for at least 6 months and resistance fighter in the conservative treatment Narrow lumbar canal and\or spondylolisthesis with neurological disorder associated with signs of primary instability or induced to neurological liberation Patient requiring a surgery on a single interbody level. Given informed consent Patient with French health system Exclusion Criteria: For women: no efficient contraception (intra uterine device, or contraceptive pill) Pregnant or feeding women Surgery zone local infection local Lumbar interbody fusion of more than two levels Spondylolisthesis of high rank (stage 3 or 4 of the classification of Meyerding) Scoliosis lumbar vertebra gives a complex to (Cobb angle> 40°) All surgical contraindications Severe hyperparathyroidism: calcium > 2,45 mmol/l and [PTH] ≥ 50pg / ml Uncontrolled diabetes (untreated or non stabilized by treatment) Long corticoid treatment (more than 6 months and stopped since less than 3 months) Current Chemotherapy or during the last three months Antecedent of regional radiotherapy All contraindication to MatriTM BONE: osteomyelitis, bone degenerative disease or necrosis of surgery site. Known turned out Osteoporosis untreated (dexa: > 2 DS) Subject participating in another research including a period of always current exclusion in the pre-inclusion Person placed under protection of justice Severely altered physical and\or psychological Health, which according to, the investigator, can affect to participant's compliance to the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Charles LE HUEC, PUPH
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Antoine BENARD, MD
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Study Chair
Facility Information:
Facility Name
Unité d'Orthopédie-Traumatologie rachis II, Pellegrin
City
Bordeaux
ZIP/Postal Code
33076
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
16985443
Citation
Anand N, Hamilton JF, Perri B, Miraliakbar H, Goldstein T. Cantilever TLIF with structural allograft and RhBMP2 for correction and maintenance of segmental sagittal lordosis: long-term clinical, radiographic, and functional outcome. Spine (Phila Pa 1976). 2006 Sep 15;31(20):E748-53. doi: 10.1097/01.brs.0000240211.23617.ae.
Results Reference
background
PubMed Identifier
19050586
Citation
Battie MC, Videman T, Levalahti E, Gill K, Kaprio J. Genetic and environmental effects on disc degeneration by phenotype and spinal level: a multivariate twin study. Spine (Phila Pa 1976). 2008 Dec 1;33(25):2801-8. doi: 10.1097/BRS.0b013e31818043b7.
Results Reference
background
PubMed Identifier
19111259
Citation
Battie MC, Videman T, Kaprio J, Gibbons LE, Gill K, Manninen H, Saarela J, Peltonen L. The Twin Spine Study: contributions to a changing view of disc degeneration. Spine J. 2009 Jan-Feb;9(1):47-59. doi: 10.1016/j.spinee.2008.11.011.
Results Reference
background
PubMed Identifier
19111510
Citation
Carter JD, Swearingen AB, Chaput CD, Rahm MD. Clinical and radiographic assessment of transforaminal lumbar interbody fusion using HEALOS collagen-hydroxyapatite sponge with autologous bone marrow aspirate. Spine J. 2009 Jun;9(6):434-8. doi: 10.1016/j.spinee.2008.11.004. Epub 2008 Dec 25.
Results Reference
background
PubMed Identifier
18357449
Citation
Chen Z, Zhao J, Liu A, Yuan J, Li Z. Surgical treatment of recurrent lumbar disc herniation by transforaminal lumbar interbody fusion. Int Orthop. 2009 Feb;33(1):197-201. doi: 10.1007/s00264-008-0531-1. Epub 2008 Mar 21.
Results Reference
background
PubMed Identifier
19058702
Citation
el-Masry MA, Khayal H, Salah H. Unilateral transforaminal lumbar interbody fusion (TLIF) using a single cage for treatment of low grade lytic spondylolisthesis. Acta Orthop Belg. 2008 Oct;74(5):667-71.
Results Reference
background
PubMed Identifier
19525786
Citation
Goyal N, Wimberley DW, Hyatt A, Zeiller S, Vaccaro AR, Hilibrand AS, Albert TJ. Radiographic and clinical outcomes after instrumented reduction and transforaminal lumbar interbody fusion of mid and high-grade isthmic spondylolisthesis. J Spinal Disord Tech. 2009 Jul;22(5):321-7. doi: 10.1097/BSD.0b013e318182cdab.
Results Reference
background
PubMed Identifier
16599424
Citation
Houten JK, Post NH, Dryer JW, Errico TJ. Clinical and radiographically/neuroimaging documented outcome in transforaminal lumbar interbody fusion. Neurosurg Focus. 2006 Mar 15;20(3):E8. doi: 10.3171/foc.2006.20.3.9.
Results Reference
background
PubMed Identifier
19404155
Citation
Jagannathan J, Sansur CA, Oskouian RJ Jr, Fu KM, Shaffrey CI. Radiographic restoration of lumbar alignment after transforaminal lumbar interbody fusion. Neurosurgery. 2009 May;64(5):955-63; discussion 963-4. doi: 10.1227/01.NEU.0000343544.77456.46.
Results Reference
background
PubMed Identifier
16816765
Citation
Lauber S, Schulte TL, Liljenqvist U, Halm H, Hackenberg L. Clinical and radiologic 2-4-year results of transforaminal lumbar interbody fusion in degenerative and isthmic spondylolisthesis grades 1 and 2. Spine (Phila Pa 1976). 2006 Jul 1;31(15):1693-8. doi: 10.1097/01.brs.0000224530.08481.4e.
Results Reference
background
PubMed Identifier
19482519
Citation
Rihn JA, Patel R, Makda J, Hong J, Anderson DG, Vaccaro AR, Hilibrand AS, Albert TJ. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J. 2009 Aug;9(8):623-9. doi: 10.1016/j.spinee.2009.04.004. Epub 2009 May 30.
Results Reference
background
PubMed Identifier
19475434
Citation
Rihn JA, Makda J, Hong J, Patel R, Hilibrand AS, Anderson DG, Vaccaro AR, Albert TJ. The use of RhBMP-2 in single-level transforaminal lumbar interbody fusion: a clinical and radiographic analysis. Eur Spine J. 2009 Nov;18(11):1629-36. doi: 10.1007/s00586-009-1046-1. Epub 2009 May 28.
Results Reference
background
PubMed Identifier
15699810
Citation
Sasso RC, LeHuec JC, Shaffrey C; Spine Interbody Research Group. Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment. J Spinal Disord Tech. 2005 Feb;18 Suppl:S77-81. doi: 10.1097/01.bsd.0000112045.36255.83.
Results Reference
background
PubMed Identifier
18939923
Citation
Schleicher P, Beth P, Ottenbacher A, Pflugmacher R, Scholz M, Schnake KJ, Haas NP, Kandziora F. Biomechanical evaluation of different asymmetrical posterior stabilization methods for minimally invasive transforaminal lumbar interbody fusion. J Neurosurg Spine. 2008 Oct;9(4):363-71. doi: 10.3171/SPI.2008.9.10.363.
Results Reference
background
PubMed Identifier
19565252
Citation
Xiao Y, Li F, Chen Q. Transforaminal lumbar interbody fusion with one cage and excised local bone. Arch Orthop Trauma Surg. 2010 May;130(5):591-7. doi: 10.1007/s00402-009-0917-6. Epub 2009 Jun 30.
Results Reference
background
PubMed Identifier
19589277
Citation
Xiao YX, Chen QX, Li FC. Unilateral transforaminal lumbar interbody fusion: a review of the technique, indications and graft materials. J Int Med Res. 2009 May-Jun;37(3):908-17. doi: 10.1177/147323000903700337.
Results Reference
background
PubMed Identifier
18685873
Citation
Yan DL, Pei FX, Li J, Soo CL. Comparative study of PILF and TLIF treatment in adult degenerative spondylolisthesis. Eur Spine J. 2008 Oct;17(10):1311-6. doi: 10.1007/s00586-008-0739-1. Epub 2008 Aug 7.
Results Reference
background

Learn more about this trial

Efficacy and Safety Study of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Bone Marrow

We'll reach out to this number within 24 hrs